BackGossamer Bio Overview

Gossamer Bio Receivables

Latest receivables for GOSS: $0.

Get informed when a big investor buys or sells

+ Follow
Receivables
$0.00
↓ 100.00% YoYΔ $-7.98M vs prior year quarter

Peer trimmed avg / median

Loading

Gossamer Bio Receivables History

Loading

Gossamer Bio vs. peers: Receivables Comparison

Loading

Gossamer Bio Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Gossamer Bio (GOSS) FAQ

As of the most recent data (June 2026), GOSS shows a receivables of $0. That compares with $8M in the prior-year period — down 100.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, GOSS's receivables is now $0 (was $8M) — a 100.0% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Gossamer Bio is outperforming or lagging.

Tracking GOSS's receivables over time shows whether Gossamer Bio is scaling, shrinking, or reshaping that part of the business. The current reading is $0 That compares with $8M in the prior-year period — down 100.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Gossamer Bio's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $0) with ownership activity and broader fundamentals.

Gossamer Bio's receivables is $0; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.